A 3-Month analysis of disability, quality of life, and disease course in patients with migraine

Headache

Volumn 53, Issue 2, 2013, Pages 297-309

  Raggi, Alberto ^a   Leonardi, Matilde ^a   Bussone, Gennaro ^a   D'Amico, Domenico ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

disability; longitudinal study; Medical Outcome Survey 36 Item Short Form Health Survey; migraine; Migraine Disability Assessment; second version; World Health Organization Disability Assessment Schedule

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MAGNESIUM SALT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN ANTAGONIST; TRIPTAN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EFFECT SIZE; FEMALE; FOLLOW UP; HEADACHE; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOME SURVEY 36 ITEM SHORT FORM HEALTH SURVEY; MIGRAINE; MIGRAINE DISABILITY ASSESSMENT; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; STUDENT T TEST; TREATMENT DURATION; WORLD HEALTH ORGANIZATION DISABILITY ASSESSMENT SCHEDULE SECOND VERSION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISABILITY EVALUATION; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; QUALITY OF LIFE; STATISTICS AS TOPIC; TRYPTAMINES; YOUNG ADULT;

EID: 84874445218     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02279.x     Document Type: Article

References (71)

1. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J,. Epidemiology of headache in Europe. Eur J Neurol. 2006; 13: 333-345.
2. Smitherman TA, McDermott MJ, Buchanan EM,. Negative impact of episodic migraine on a university population: Quality of life, functional impairment, and comorbid psychiatric symptoms. Headache. 2011; 51: 581-589.
3. Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: Results from the American Migraine Prevalence and Prevention study. Headache. 2012; 52: 3-17.
4. Koppen H, Palm-Meinders I, Kruit M, et al. The impact of a migraine attack and its after-effects on perceptual organization, attention, and working memory. Cephalalgia. 2011; 31: 1419-1427.
5. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc. 2001; 76: 1093-1101.
6. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: The Eurolight project. Eur J Neurol. 2012; 19: 703-711.
7. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache. 2011; 51: 1058-1077.
8. Stewart WF, Bruce C, Manack A, Buse DC, Varon SF, Lipton RB,. A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: Results of the American Migraine Prevalence and Prevention Study. J Occup Environ Med. 2011; 53: 1161-1171.
9. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011; 77: 1465-1472.
10. Burton WN, Landy SH, Downs KE, Runken MC,. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009; 84: 436-445.
11. Silberstein SD, Cady RK, Sheftell FD, Almas M, Parsons B, Albert KS,. Efficacy of eletriptan in migraine-related functional impairment: Functional and work productivity outcomes. Headache. 2007; 47: 673-682.
12. Lainez MJA, Lopez A, Pascual AM,. Effects on productivity and quality of life of rizatriptan for acute migraine: A workplace study. Headache. 2005; 45: 883-890.
13. Dowson A, Bundy M, Salt R, Kilminster S,. Patient preference for triptan formulations: A prospective study with zolmitriptan. Headache. 2007; 47: 1144-1151.
14. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG,. Sumatriptan injection reduces productivity loss during a migraine attack. Arch Intern Med. 1998; 158: 1013-1038.
15. Cortelli P, Dahlöf C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non workplace productivity. Pharmacoeconomics. 1997; 11: S35-S42.
16. Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer MS,. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia. 2000; 20: 830-834.
17. Mula M, Viana M, Jauch R, et al. Health-related quality of life measures and psychiatric comorbidity in patients with migraine. Eur J Neurol. 2009; 16: 1017-1021.
18. Park JW, Shin HE, Kim JS, Lee KS,. Assessing migraine disability by diary-based measurement: Relationship to the characteristics of individual headache attacks. Eur J Neurol. 2008; 15: 817-821.
19. Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L,. The impact of migraine prevention on daily activities: A longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes. 2007; 5: 56.
20. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007; 6: 1054-1062.
21. Freitag F,. The cycle of migraine: Patients' quality of life during and between migraine attacks. Clin Ther. 2007; 29: 939-949.
22. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210.
23. D'Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia. 2006; 26: 691-696.
24. Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D'Amico D,. Disability and quality of life in different primary headaches: Results from Italian studies. Neurol Sci. 2004; 25: S105-S107.
25. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF,. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003; 23: 441-450.
26. Smith TR, Nicholson RA, Banks JW,. Migraine education improves quality of life in a primary care setting. Headache. 2010; 50: 600-612.
27. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754-763.
28. Lipton RB, Bigal ME, Stewart WF,. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology. 2005; 65: S50-S58.
29. Smith T, Blumenthal H, Diamond M, et al. Sumatriptan/naproxen sodium for migraine: Efficacy, health related quality of life, and satisfaction outcomes. Headache. 2007; 47: 683-692.
30. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD,. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia. 1997; 17: 867-872.
31. Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B,. Treatment satisfaction, functional status, and health related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001; 23: 127-145.
32. Lofland JH, Johnson NE, Batenhorst AS, Nash DB,. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective. Arch Intern Med. 1999; 159: 857-863.
33. Sculpher M, Millson D, Meddis D, Poole L,. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine. The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002; 20: 91-100.
34. Freitag F, Smith T, Mathew N, et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: Results from the AEGIS trial. Headache. 2008; 48: 341-354.
35. Pascual J,. Clinical benefits of early triptan therapy for migraine. Headache. 2002; 42: S10-S17.
36. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006; 46: 914-924.
37. Kwong WJ, Taylor FR, Adelman JU,. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. J Occup Environ Med. 2005; 47: 1167-1173.
38. Valade D,. Early treatment of acute migraine: New evidence of benefits. Cephalalgia. 2009; 29: S15-S21.
39. Pradalier A, Lantéri-Minet M, Géraud G, Allain H, Lucas C, Delgado A,. The PROMISE Study: PROphylaxis of MIgraine with SEglor (Dihydroergotamine Mesilate) in French primary care. CNS Drugs. 2004; 18: 1149-1163.
40. Garcia-Monco JC, Foncea N, Bilbao A, Ruiz de Velasco I, Gomez-Beldarrain M,. Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. Cephalalgia. 2007; 27: 920-928.
41. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G,. Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA. 2003; 289: 65-69.
42. Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ,. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc. 2006; 81: 1311-1319.
43. Cady R, Schreiber C,. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008; 48: 900-913.
44. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: A double-blind study. Eur Neurol. 2008; 59: 237-242.
45. Burk CT, Gilderman A, Salas J, Berenbeim D, Nichol MB,. The impact of an over-the-counter migraine medication program on quality of life. Headache. 2003; 43: 191-201.
46. Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweifler RM,. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache. 2006; 46: 726-731.
47. Lemstra M, Stewart B, Olszynski WP,. Effectiveness of multidisciplinary intervention in the treatment of migraine: A randomized clinical trial. Headache. 2002; 42: 845-854.
48. Osün Narin S, Pinar L, Erbas D, Oztürk V, Idiman F,. The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil. 2003; 17: 624-630.
49. Merelle SY, Sorbi MJ, van Doornen LJ, Passchier J,. Lay trainers with migraine for a home-based behavioral training: A 6-month follow-up study. Headache. 2008; 48: 1311-1325.
50. Nicholson R, Nash J, Andrasik F,. A self-administered behavioral intervention using tailored messages for migraine. Headache. 2005; 45: 1124-1139.
51. World Health Organization. The International Classification of Functioning, Disability and Health-ICF. Geneva: WHO; 2001.
52. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004; 24: S1-S160.
53. Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 medication-overuse headache. Cephalalgia. 2005; 25: 460-465.
54. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999; 53: 988-994.
55. D'Amico D, Mosconi P, Genco S, et al. The Migraine Disability Assessment (MIDAS) questionnaire: Translation and reliability of the Italian version. Cephalalgia. 2001; 21: 947-952.
56. Ustün TB, Chatterji S, Kostanjsek N, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ. 2010; 88: 815-823.
57. Federici S, Meloni F, Mancini A, Lauriola M, Olivetti Belardinelli M,. World Health Organisation Disability Assessment Schedule II: Contribution to the Italian validation. Disabil Rehabil. 2009; 31: 553-564.
58. Ware JE,. SF-36 health survey update. Spine. 2000; 25: 3130-3139.
59. Apolone G, Mosconi P,. The Italian SF-36 health survey: Translation, validation and norming. J Clin Epidemiol. 1998; 51: 1025-1036.
60. Kazis LE, Anderson JJ, Meenan RF,. Effect size for interpreting changes in health status. Med Care. 1989; 27: S178-S189.
61. Norman GR, Startford P, Regehr G,. Methodological problems in the retrospective computation of responsiveness to change: The lesson of Cronbach. J Clin Epidemiol. 1997; 50: 869-879.
62. Leonardi M, Raggi A, Bussone G, D'Amico D,. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache. 2010; 50: 1576-1586.
63. Raggi A, Leonardi M, Bussone G, D'Amico D,. Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life. Neurol Sci. 2011; 32: 387-392.
64. Raggi A, Leonardi M, Giovannetti A, Curone M, Bussone G, D'Amico D,. A longitudinal evaluation of changes in disability and quality of life in a sample of women with migraine. Neurol Sci. 2011; 32: S189-S191.
65. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
66. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000; 20: 765-786.
67. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981.
68. Bordini CA, Mariano da Silva H, Garbelini RP, Teixeira SO, Speciali JG,. Effect of preventive treatment on health-related quality of life in episodic migraine. J Headache Pain. 2005; 6: 387-391.
69. Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R,. Triptans in the Italian population: A drug utilization study and a literature review. J Headache Pain. 2008; 9: 71-76.
70. Pavone E, Banfi R, Vaiani M, Panconesi A,. Patterns of triptans use: A study based on the records of a community pharmaceutical department. Cephalalgia. 2007; 27: 1000-1004.
71. Garin O, Ayuso-Mateos JL, Almansa J, et al. Validation of the World Health Organization Disability Assessment Schedule (WHODAS-2) in patients with chronic diseases. Health Qual Life Outcomes. 2010; 8: 51.